A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Delafloxacin (Primary) ; Delafloxacin (Primary) ; Linezolid; Moxifloxacin; Moxifloxacin
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms DEFINE-CABP
- Sponsors Melinta Therapeutics
- 13 Mar 2018 According to a Melinta Therapeutics media release, data is expected in 2018.
- 15 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 15 Dec 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.